BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 3466574)

  • 1. [A prospective randomized trial comparing epirubicin and doxorubicin in advanced or recurrent breast cancer].
    Taguchi T; Ogawa M; Izuo M; Terasawa T; Yoshida M; Nakajima M
    Gan To Kagaku Ryoho; 1986 Dec; 13(12):3498-507. PubMed ID: 3466574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study.
    Andersson M; Daugaard S; von der Maase H; Mouridsen HT
    Cancer Treat Rep; 1986 Oct; 70(10):1181-6. PubMed ID: 3530444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phase II study of epirubicin on breast cancer: a cooperative group study].
    Tominaga T; Kitamura M; Nomura Y; Abe O; Enomoto K; Ikeda T; Izuo M; Iino Y; Taguchi T; Tamura K
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2187-92. PubMed ID: 3459397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination chemotherapy using low-dose epirubicin and vindesine in patients with metastatic breast cancer].
    Takatsuka Y; Nakayama H; Kawahara T
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 1):667-71. PubMed ID: 2965547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of weekly low-dose 4'-epi-doxorubicin in advanced postmenopausal breast cancer.
    Jones WG; Mattsson W
    Cancer Treat Rep; 1984 Apr; 68(4):675-7. PubMed ID: 6585271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase II study of epirubicin in inoperable or recurrent gastric cancer].
    Sakata Y; Yoshida Y
    Gan To Kagaku Ryoho; 1986 May; 13(5):1887-92. PubMed ID: 3458431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
    Tominaga T; Kitamura M; Hayashi K; Takahashi I; Kosaki G
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1669-74. PubMed ID: 6591857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical evaluation of 4'-epi-doxorubicin.
    Hurteloup P; Cappelaere P; Armand JP; Mathé G
    Cancer Treat Rep; 1983 Apr; 67(4):337-41. PubMed ID: 6573956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intra-arterial infusion chemotherapy in the treatment of advanced breast cancer--doxorubicin versus epirubicin].
    Yayoi E; Furukawa J; Takatsuka Y; Kobayashi T; Aikawa T; Maeura Y; Kaji M; Kotsuma Y
    Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1621-4. PubMed ID: 1530320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer--a comparative study by a double blind method with tamoxifen].
    Nomura Y; Tominaga T; Abe O; Izuo M; Ogawa N
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):247-58. PubMed ID: 8434963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
    Focan C; Graas MP; Beauduin M; Canon JL; Salmon JP; Jerusalem G; Focan-Henrard D; Lobelle JP; Schallier D
    Anticancer Res; 2005; 25(2B):1211-7. PubMed ID: 15865068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients.
    Martini A; Moro E; Pacciarini MA; Tamassia V; Natale N; Piazza E
    Int J Clin Pharmacol Res; 1984; 4(3):231-8. PubMed ID: 6593309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer].
    Abe O; Tominaga T; Enomoto K; Abe R; Iino Y; Koyama H; Fujimoto M; Nomura Y; Tanaka T
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2160-8. PubMed ID: 3717960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.
    Kawai S; Tani M; Okamura J; Ogawa M; Ohashi Y; Monden M; Hayashi S; Inoue J; Kawarada Y; Kusano M; Kubo Y; Kuroda C; Sakata Y; Shimamura Y; Jinno K; Takahashi A; Takayasu K; Tamura K; Nagasue N; Nakanishi Y; Makino M; Masuzawa M; Yumoto Y; Mori T; Oda T
    Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-38-S6-45. PubMed ID: 9151915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
    Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
    J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer.
    Pavesi L; Preti P; Da Prada G; Pedrazzoli P; Poggi G; Robustelli della Cuna G
    Anticancer Res; 1995; 15(2):495-501. PubMed ID: 7763029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A comparison of two doses of tamoxifen in patients with advanced breast cancer: 20 mg/day versus 40 mg/day].
    Takatsuka Y; Yayoi E; Inaji H; Aikawa T
    Gan To Kagaku Ryoho; 1989 May; 16(5):2093-7. PubMed ID: 2658841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of CGS16949A in advanced or recurrent breast cancer--a multi-institutional late phase II clinical trial].
    Aoyama H; Asaishi K; Abe R; Kajiwara T; Enomoto K; Yoshida M; Ohasi Y; Tominaga T; Abe O
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):477-84. PubMed ID: 8129388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.